— Know what they know.
Not Investment Advice
Also trades as: 2877.HK (HKSE) · $vol 1M · CSWYY (OTC) · $vol 0M

CSWYF OTC

China Shineway Pharmaceutical Group Limited
1W: +0.0% 1M: -6.9% 3M: -12.7% YTD: -12.7% 1Y: -12.7% 3Y: +16.9% 5Y: +3.9%
$1.00
+0.00 (+0.00%)
 
OTC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 63 · $758.4M mcap · 255M float · 0.0000% daily turnover
Smart Money Score
No convergence signal
Key Statistics
Market Cap$758.4M
52W Range0.9253-1.004
Volume100
Avg Volume68
Beta0.72
Dividend$0.08
Analyst Ratings
No analyst coverage
Company Info
CEOZhenjiang Li
Employees2,822
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2020-02-18
Luan Cheng District
Shijiazhuang 051430
CN
86 31 1880 30066
About China Shineway Pharmaceutical Group Limited

China Shineway Pharmaceutical Group Limited functions as an investment holding company, primarily engaged in the development, manufacturing, and commercialization of traditional Chinese medicines. Its operations span across the People's Republic of China and Hong Kong. The company's diverse product portfolio includes contemporary Chinese medicines, supplied in formats such as soft capsules, granules, and injections, alongside traditional Chinese medicine (TCM) Formula Granules. These offerings target a wide array of therapeutic fields, including cardiovascular and cerebrovascular health, anti-viral applications, orthopedic care, pediatric medicine, women's health, and digestive system disorders. Beyond pharmaceuticals, the company also participates in the trading of agricultural goods. Established in 2004, China Shineway Pharmaceutical Group Limited has its headquarters situated in Shijiazhuang, PRC, and operates as a subsidiary of Forway Investment Limited.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms